Disclosures for "Safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous and intravenous ALXN1720 in healthy volunteers: a phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study ")
-
Dr. Ortiz has received personal compensation for serving as an employee of Alexion. Dr. Ortiz has received stock or an ownership interest from Alexion.
-
Dr. McEneny has received personal compensation for serving as an employee of Alexion Pharmaceuticals Inc.. Dr. McEneny has stock in Alexion Pharmaceuticals.
-
Dr. Amancha has nothing to disclose.
-
Mrs. Rice has received personal compensation for serving as an employee of AstraZeneca. Mrs. Rice has stock in AstraZeneca.
-
Dr. Scholz has received personal compensation for serving as an employee of Alexion AstraZeneca Rare Disease. Dr. Scholz has stock in Alexion AstraZeneca Rare Disease. Dr. Scholz has stock in Biogen.
-
Dr. Rakhade has received personal compensation for serving as an employee of Alexion Pharmaceuticals . Dr. Rakhade has stock in Alexion Pharmaceuticals. Dr. Rakhade has stock in Astra Zeneca. Dr. Rakhade has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Yee has nothing to disclose.